Daewoong Pharma's ‘Nabota’, No. 1 Korean Toxin Company... $55.9 Million In The 1st Half Year
Daewoong Pharmaceutical(Daewoong) announced on the 27th that sales of its botulinum toxin product Nabota recorded $55.9 million in the first half of this year. ...
- Daewoong Pharmaceutical Obtained ‘Nabota’ Patent For Migraine Treatment In The US
- Daewoong Pharma 'Envlo', A New Treatment for Diabetes...Anticipating 'Game Changer' in the Market
- The 2nd Botox War 'Origin Disputes'... Medytox "Release Information" vs. Hugel "No Agreement"
- Daewoong Pharmaceutical “Don’t Think Much Will Change”...Under Re-investigation of ‘Medytox Botox Stealing Suspicion’